Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046585 · ClinicalTrials.gov registry record
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
A clinical trial of Colorectal Cancer, sponsored by Natera.
- Recruiting
- Registry status
- 25,000
- Enrollment target
- 1
- Study location
NCT07046585: Recruiting study of Colorectal Cancer, sponsored by Natera.
NCT07046585 is a study of Colorectal Cancer that is actively recruiting participants, run by Natera. The registered enrollment target is 25,000 participants, above the 1,479-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (1590% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07046585, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Natera.
- RECRUITING
- Registry status
- 25,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.
Primary Outcome
The primary outcomes of this study are sensitivity of the Natera CRC Screening Test for the detection of colorectal cancer (CRC) and specificity of the test for advanced neoplasia (AN), as assessed by agreement of the Natera CRC Screening test with colonoscopy findings.
Conditions Studied
Study Locations (1)
Texas
- Natera, Inc - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,000 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2033-09-30 |
What NCT07046585 shows while recruiting
NCT07046585 is an observational study that tracks outcomes without assigning an intervention. Its 25,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,479-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (1590% higher).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07046585 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07046585 about?
NCT07046585 is a clinical study titled "Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)". The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.
What is the current status of trial NCT07046585?
This trial is currently recruiting. The enrollment target is 25,000 participants. The study started on 2025-05-30. Estimated completion is 2033-09-30.
What conditions does trial NCT07046585 study?
This clinical trial studies the following conditions: Colorectal Cancer.
Who is sponsoring clinical trial NCT07046585?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07046585 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07046585's enrollment target sits among peer trials
25,000 5th of 381 higher than 377 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
- NCT06773897 · 25,000 participants
Rutgers University Study of the Genetics of Breast Cancer.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI